Visitors to ViewRay's booth #1317 can observe first-hand clinical experience with the world's first commercially available MR-Linac from clinicians at Henry Ford Cancer Institute, as well as MRIdian presentations from institutions around the world including SNUH; UCLA; Gemelli ART; VUmc; and Washington University. These presentations will take place at various times from Sunday, September 24 through Tuesday, September 26.

ViewRay will also host one of ASTRO's Industry Expert Theater sessions, titled "Pioneering Clinical Experience with MRIdian Linac & Improved Clinical Outcomes with On-Table Adaptive RT," which will take place on Tuesday, September 26 at 12:30 p.m. in Theater 1. The session will feature presentations by three speakers: Carri Glide-Hurst, Ph.D. from Henry Ford Cancer Institute will present on the initial clinical experience with MRIdian Linac; Maria Thomas, M.D., Ph.D. from Washington University will discuss accelerated treatments of breast cancer with MRIdian; and Frank Lagerwaard, M.D., Ph.D., from VUmc will present a streamlined process for online adaptive treatment of pancreatic cancer with MRIdian.


A full list of MRIdian-focused ASTRO Scientific Session presentations and in-booth talks is available at http://www.viewray.com/ASTRO_2017.

About ViewRay

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

SOURCE ViewRay, Inc.

Back to HCB News

MRI Homepage